Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
10.
Actas Dermosifiliogr ; 114(1): 49-53, 2023 Jan.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-35963337

RESUMO

Immunosuppressants and immunomodulators are widely used in dermatology. Some of these drugs, however, can increase the risk of severe COVID-19. New antivirals against SARS-CoV-2 have been shown to reduce progression to COVID-19 pneumonia in susceptible patients, but their availability is limited. On May 23, 2022, the Spanish Agency for Medicines and Medical Devices (AEMPS) updated its priority eligibility criteria for SARS-CoV-2 antiviral therapy. In this practical guide, we review the indications for these new drugs and provide guidance on which patients with mild to moderate COVID might benefit from their use in dermatology.


Assuntos
COVID-19 , Dermatologia , Humanos , SARS-CoV-2 , Imunossupressores/efeitos adversos , Suscetibilidade a Doenças/induzido quimicamente , Antivirais/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA